If you’re working in the pharma supply chain, especially as a manufacturer or distributor of active pharmaceutical ingredients (APIs), you’ve definitely crossed paths with WHO prequalification (PQL) questions lately. As a PDE-5 inhibitor API supplier, I get asked this every single week: are these APIs actually on the WHO prequalified list? Let’s break this down straight, no jargon, just the real deal from someone who’s been in this lane for 8 years. PDE-5 Inhibitor APIs

First, let’s keep this simple: PDE-5 inhibitors are the core ingredients in meds for ED and pulmonary arterial hypertension (PAH), right? The main ones you hear about are sildenafil, tadalafil, vardenafil, and avanafil. Most small-scale API makers like us stick to the first two because they’ve been around longer and have more regulatory clarity. Now, WHO prequalification isn’t just a stamp of approval—it’s the green light for APIs to be used in WHO-recommended meds, especially for low- and middle-income countries (LMICs) where access to affordable, safe drugs matters most.
Here’s the thing: PDE-5 inhibitor APIs aren’t a one-size-fits-all category for WHO PQL. Some of the big, old API manufacturers already have sildenafil and tadalafil prequalified, but most smaller players? Not yet. Wait, let’s clarify: prequalification for APIs vs. prequalification for finished medicines. A lot of folks mix those up. WHO PQL for APIs means the API meets their strict standards for quality, safety, and consistency. For finished drugs, it means the whole product (API plus excipients, packaging, etc.) checks out. So when I tell clients I supply PDE-5 inhibitor APIs, I always specify which ones are prequalified and which are in the pipeline.
Let’s get specific with the ones that actually have WHO PQL as of 2024. Sildenafil citrate API—yes, several major API makers have this prequalified, including a couple that work with WHO directly on supply for public health programs. Tadalafil API? Also prequalified, especially the anhydrous and dihydrate forms, which are the ones used in both ED and PAH meds. Now, vardenafil and avanafil—they’re newer, and I don’t know of any WHO-prequalified API for those right now. That’s not a knock on the molecules, it’s just that the testing and documentation for prequalification take time, especially if you’re a smaller supplier without the big regulatory teams.
Why does this matter for you, especially if you’re sourcing APIs? If you’re selling to LMICs, almost any public or non-profit buyer will require WHO-prequalified APIs for tender bids. They can’t use un-prequalified stuff because it won’t pass their quality checks, and it won’t be eligible for Gavi funding or other global health programs. If you’re supplying to the private sector (like branded drug makers or pharmacies in wealthy countries), WHO PQL is still a big signal that your API is consistent and safe, even if it’s not a hard requirement.
As a supplier, we’ve walked this tightrope for years. We originally focused on generic sildenafil and tadalafil because those had clear regulatory paths, and we knew early on that getting WHO PQL for our APIs would be key to serving both public and private clients. Let me be transparent: when we started, we didn’t have prequalified API. We spent 18 months on the testing, documentation, and audit process to get our sildenafil API on the WHO PQL list. It was brutal—we had to submit 10+ batches of stability data, pass a GMP audit by WHO’s experts, and prove that every step of our manufacturing process doesn’t compromise quality. It’s not cheap, it’s not fast, but it’s worth it when a public health agency contacts us because they know our API is approved for their programs.
Wait, but what about if you’re a buyer who needs PDE-5 inhibitor API that’s not prequalified? We also work with that. For example, some private-label drug makers want custom formulations for niche markets, or they’re testing new PAH combinations that use a mix of prequalified and proprietary APIs. We don’t hide that our other PDE-5 APIs (like vardenafil, which we’re currently working on for prequalification) aren’t prequalified yet—we tell clients up front, so there’s no surprises. Last year, we had a small pharmaceutical startup reach out to us, and they said they appreciated the honesty because they didn’t need WHO prequalification for their domestic market. We supplied them with our non-prequalified tadalafil, and they came back three months later for a bulk order because the price and quality were way better than their previous supplier.
I should also address a common misconception: just because an API isn’t WHO prequalified doesn’t mean it’s unsafe. WHO PQL is a very high bar, but there are tons of API makers (including us, for some products) that meet strict ICH guidelines and FDA standards without going through the formal prequalification process. WHO prequalification is tailored to the needs of global health programs, so it’s not the only measure of a good API. But if your work involves any kind of international tender, public health funding, or supply to countries that require it, prequalification is non-negotiable.
Another point: the WHO prequalification list for APIs updates every quarter. Last year, two more tadalafil API manufacturers got prequalified, and they’re now part of the supply chain for Gavi’s ED treatment programs. We’re actually planning to apply for prequalification for our avanafil API in 2025, so keep an eye on the list if that’s something you care about. We don’t want to rush it—we want to make sure every batch we submit meets WHO’s exact standards, because our reputation is tied to the drugs that end users take.
I’ve had so many clients ask me, “Can I use your PDE-5 inhibitor APIs in a WHO-prequalified finished drug?” The answer is: if the API itself is prequalified, yes. If it’s not, no. It’s that simple. A lot of drug makers try to cut corners by using an API that’s not prequalified in a bid, but WHO will reject the finished drug during their audit because the API doesn’t meet their requirements. That’s why we’re upfront with clients about which of our products are eligible.
Let’s talk about why PDE-5 inhibitors are a big focus for WHO prequalification. ED meds are often stigmatized, so access to affordable, generic versions in LMICs was really limited until a few years ago. WHO started prioritizing PDE-5 APIs for prequalification because ED is a common condition that’s often untreated in those countries, and generic versions can make treatment accessible for millions of people. The same goes for PAH—PDE-5 inhibitors are a key treatment for that, and WHO has pushed for prequalification for those APIs to keep PAH drugs affordable and available.
As a supplier, we also care a lot about sustainability and transparency in our supply chain. Our PDE-5 inhibitor APIs are manufactured in a facility that’s ISO 9001 certified, and we share full batch data with every client, whether they need WHO prequalification or not. We don’t hold back information about our manufacturing process, and we never cut corners on raw material quality. I think that’s why we’ve been able to build long-term relationships with clients, from small local pharma startups to big global health organizations.
Wait, let’s wrap this up. If you’re looking for PDE-5 inhibitor APIs, the first question you should ask your supplier is: which ones are WHO prequalified? As someone who’s been in this industry, I can tell you that there’s a lot of noise out there, and some suppliers will overstate their products’ credentials. We make a point to be clear: our sildenafil and tadalafil APIs are WHO prequalified, our vardenafil is not yet, and our avanafil is in the works. No lies, no exaggeration.
If you’re a buyer looking for PDE-5 inhibitor APIs, whether you need WHO prequalified ones for global tenders or non-prequalified ones for your domestic market, don’t hesitate to reach out to us. We can talk through your specific needs, share our batch data, and help you find the right API for your project. We’re not here to push a product you don’t need—we’re here to build a long-term partnership, just like we have with dozens of clients over the years.
At the end of the day, whether you’re a pharma maker, a distributor, or someone who just cares about accessible, safe medication, the WHO prequalification status of APIs matters. For PDE-5 inhibitors, it’s a key marker of quality and eligibility for public health programs, and as a supplier, we take that responsibility seriously. We’ll keep updating our prequalification applications, keep our processes transparent, and keep supplying APIs that meet the needs of every client, no matter how big or small.
Food Additives Raw Materials References:
- World Health Organization. (2024). WHO Prequalification of Active Pharmaceutical Ingredients: Eligibility and Requirements.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2023). ICH Q7 Guidelines for Good Manufacturing Practice of Active Pharmaceutical Ingredients.
- Gavi, the Vaccine Alliance. (2023). Procurement Guidelines for Active Pharmaceutical Ingredients for Generic Medicines.
- U.S. Food and Drug Administration. (2024). Generic Drugs: Active Pharmaceutical Ingredients – Quality Standards and Compliance.
- World Health Organization. (2023). Model List of Essential Medicines: PDE-5 Inhibitors for Erectile Dysfunction and Pulmonary Arterial Hypertension.
Henan Jinyi Import & Export Co., Ltd.
Address: Block A, Building 3, No.7 Guoji Road, Jinshui District, Zhengzhou City, Henan Province
E-mail: 13838041990@163.com
WebSite: https://www.jyingredients.com/